botulinum toxin A longer acting (IPN10200) / Ipsen - LARVOL DELTA

CATALPA: A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults (clinicaltrials.gov) - P2 | N=132 | Not yet recruiting | Sponsor: Ipsen

New P2 trial • CNS Disorders • Dystonia • Movement Disorders

MERANTI: A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults (clinicaltrials.gov) - P2 | N=641 | Recruiting | Sponsor: Ipsen | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Migraine • Pain

MERANTI: A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults (clinicaltrials.gov) - P2 | N=641 | Not yet recruiting | Sponsor: Ipsen

New P2 trial • CNS Disorders • Migraine • Pain

LANTIMA: A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity. (clinicaltrials.gov) - P1/2 | N=240 | Active, not recruiting | Sponsor: Ipsen | Trial completion date: Jun 2026 ➔ Oct 2027 | Trial primary completion date: Sep 2024 ➔ Oct 2027

Trial completion date • Trial primary completion date • Movement Disorders

LANTIC: A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines (clinicaltrials.gov) - P1/2 | N=727 | Recruiting | Sponsor: Ipsen | Trial primary completion date: Nov 2024 ➔ Mar 2026

Trial primary completion date

LANTIMA: A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity. (clinicaltrials.gov) - P1/2 | N=209 | Active, not recruiting | Sponsor: Ipsen | Recruiting ➔ Active, not recruiting

Enrollment closed • Movement Disorders

LANTIC: A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines (clinicaltrials.gov) - P1/2 | N=727 | Recruiting | Sponsor: Ipsen | Active, not recruiting ➔ Recruiting

Enrollment open

LANTIC: A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines (clinicaltrials.gov) - P1/2 | N=727 | Active, not recruiting | Sponsor: Ipsen | N=547 ➔ 727 | Trial primary completion date: Apr 2023 ➔ Nov 2024

Enrollment change • Trial primary completion date

LANTIMA: A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity. (clinicaltrials.gov) - P1/2 | N=209 | Recruiting | Sponsor: Ipsen | Trial completion date: Sep 2024 ➔ Jun 2026

Trial completion date • Movement Disorders

LANTIC: A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines (clinicaltrials.gov) - P1/2 | N=547 | Active, not recruiting | Sponsor: Ipsen | N=191 ➔ 547 | Trial completion date: Dec 2024 ➔ Mar 2027

Enrollment change • Trial completion date

LANTIC: A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines (clinicaltrials.gov) - P1/2 | N=191 | Active, not recruiting | Sponsor: Ipsen | Completed ➔ Active, not recruiting

Enrollment closed

LANTIC: A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines (clinicaltrials.gov) - P1/2 | N=191 | Completed | Sponsor: Ipsen | Active, not recruiting ➔ Completed

Trial completion

LANTIMA: A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity. (clinicaltrials.gov) - P1/2 | N=209 | Recruiting | Sponsor: Ipsen | Trial completion date: Mar 2024 ➔ Sep 2024 | Trial primary completion date: Mar 2024 ➔ Sep 2024

Trial completion date • Trial primary completion date • Movement Disorders

LANTIC: A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines (clinicaltrials.gov) - P1/2 | N=191 | Active, not recruiting | Sponsor: Ipsen | Recruiting ➔ Active, not recruiting | N=547 ➔ 191

Enrollment change • Enrollment closed

LANTIC: A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines (clinicaltrials.gov) - P1/2 | N=547 | Recruiting | Sponsor: Ipsen | N=110 ➔ 547

Enrollment change

LANTIC: A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines (clinicaltrials.gov) - P1/2 | N=110 | Recruiting | Sponsor: Ipsen | Active, not recruiting ➔ Recruiting | N=80 ➔ 110

Enrollment change • Enrollment open

LANTIC: A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines (clinicaltrials.gov) - P1/2 | N=80 | Active, not recruiting | Sponsor: Ipsen | Recruiting ➔ Active, not recruiting

Enrollment closed

LANTIC: A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines (clinicaltrials.gov) - P1/2 | N=110 | Recruiting | Sponsor: Ipsen | N=80 ➔ 110 | Trial completion date: Apr 2023 ➔ Oct 2023 | Trial primary completion date: Aug 2022 ➔ Feb 2023

Enrollment change • Trial completion date • Trial primary completion date

LANTIC: A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines (clinicaltrials.gov) - P1/2 | N=80 | Recruiting | Sponsor: Ipsen | N=56 ➔ 80 | Trial completion date: Nov 2022 ➔ Apr 2023 | Trial primary completion date: Mar 2022 ➔ Aug 2022

Enrollment change • Trial completion date • Trial primary completion date

LANTIC: A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines (clinicaltrials.gov) - P1/2; N=56; Recruiting; Sponsor: Ipsen; Trial completion date: Jul 2022 ➔ Nov 2022; Trial primary completion date: Nov 2021 ➔ Mar 2022

Clinical • Trial completion date • Trial primary completion date